VECTORSONIC, MODEL VU-270

• K Number: K030880
• Device Name: VECTORSONIC, MODEL VU-270
• Manufacturer: METRON MEDICAL AUSTRALIA PTY LTD
• Date Cleared: 2003-04-18 ( 29 days)
• Product Code: IMG
• Regulation Number: 890.5860
• Type: Special
• Panel: Physical Medicine
• Reference & Predicate Devices: N/A
• Predicate For: N/A

Intended Use

The indications for use for the interferential therapy are:

• Relaxation of muscle spasm: 1.
• 2. Prevention or retardation of disuse atrophy:
• 3. Increasing local blood flow;
• 4. Muscle re-education;
• Immediate post-surgical stimulation of calf muscles to prevent 5. venous thrombosis; and
• Maintaining or increasing range of motion. 6.

The indications for use for the ultrasound therapy are:

• 1. Relief or reduction of pain;
• 2. Reduction of muscle spasm;
• 3. Joint contracture; and
• 4. Local increase in circulation.

The indication for use for the combined therapy is:

• Reduction of muscle spasm. 1.

Device Description

Not Found

AI/ML Overview

This document is a 510(k) premarket notification letter from the FDA regarding the Vectorsonic Model VU 270. It confirms that the device is substantially equivalent to legally marketed predicate devices. However, the document does not contain information about acceptance criteria or a study proving the device meets those criteria.

Specifically, the document:

• Identifies the device (Vectorsonic Model VU 270) and its manufacturer.
• States the regulation number, name, and regulatory class for the device (Ultrasound and muscle stimulator, Class II).
• Lists the indications for use for interferential therapy, ultrasound therapy, and combined therapy.
• Confirms the FDA's finding of substantial equivalence.

Therefore, I cannot provide the requested information as it is not present in the provided text. The document is a regulatory approval, not a technical report detailing performance study results.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is often associated with healthcare. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus symbol.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 8 2003

Mr. David K. Toman Technical Director Metron Medical Australia Pty. Ltd. 57 Aster Avenue P.O. Box 2164 Carrum Downs Victoria, Australia 3201

Re: K030880

Trade/Device Name: Vectorsonic Model VU 270 Regulation Number: 21 CFR 890.5860 Regulation Name: Ultrasound and muscle stimulator Regulatory Class: II Product Code: IMG Dated: March 17, 2003 Received: March 20, 2003

Dear Mr. Toman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

Page 2 -- Mr. David K. Toman

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Mark N Wilkerson

Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Page 1 of 1

K030880

510 (k) NUMBER (IF KNOWN):

DEVICE NAME:

Vectorsonic Model VU 270

INDICATIONS FOR USE:

The indications for use for the interferential therapy are:

• Relaxation of muscle spasm: 1.
• 2. Prevention or retardation of disuse atrophy:
• 3. Increasing local blood flow;
• 4. Muscle re-education;
• Immediate post-surgical stimulation of calf muscles to prevent 5. venous thrombosis; and
• Maintaining or increasing range of motion. 6.

The indications for use for the ultrasound therapy are:

• 1. Relief or reduction of pain;
• 2. Reduction of muscle spasm;
• 3. Joint contracture; and
• 4. Local increase in circulation.

The indication for use for the combined therapy is:

• Reduction of muscle spasm. 1.
  Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) OR

Over-The-Counter-Use (Optional Format 1-2-96)

Mark Millan

(Division Sign-Off)
Division of General, Restorative and Neurological Devices
510(k) Number	K030880

Regulation Number and Section

§ 890.5860 Ultrasound and muscle stimulator.

(a)
Ultrasound and muscle stimulator for use in applying therapeutic deep heat for selected medical conditions —(1)Identification. An ultrasound and muscle stimulator for use in applying therapeutic deep heat for selected medical conditions is a device that applies to specific areas of the body ultrasonic energy at a frequency beyond 20 kilohertz and that is intended to generate deep heat within body tissues for the treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies. The device also passes electrical currents through the body area to stimulate or relax muscles.(2)
Classification. Class II (performance standards).(b)
Ultrasound and muscle stimulator for all other uses —(1)Identification. An ultrasound and muscle stimulator for all other uses except for the treatment of malignancies is a device that applies to the body ultrasonic energy at a frequency beyond 20 kilohertz and applies to the body electrical currents and that is intended for the treatment of medical conditions by means other than the generation of deep heat within body tissues and the stimulation or relaxation of muscles as described in paragraph (a) of this section.(2)
Classification. Class III (premarket approval).(c)
Date PMA or notice of completion of PDP is required. A PMA or notice of completion of a PDP for a device described in paragraph (b) of this section is required to be filed with the Food and Drug Administration on or before July 13, 1999 for any ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 13, 1999, been found to be substantially equivalent to an ultrasound and muscle stimulator described in paragraph (b) of this section that was in commercial distribution before May 28, 1976. Any other ultrasound and muscle stimulator described in paragraph (b) of this section shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.